tiprankstipranks
Trending News
More News >
Ocean Biomedical (OCEA)
OTHER OTC:OCEA
US Market

Ocean Biomedical (OCEA) Price & Analysis

Compare
283 Followers

OCEA Stock Chart & Stats

$0.01
-$0.06(-8.34%)
At close: 4:00 PM EST
$0.01
-$0.06(-8.34%)

Ocean Biomedical News

OCEA FAQ

What was Ocean Biomedical’s price range in the past 12 months?
Ocean Biomedical lowest stock price was <$0.01 and its highest was $2.03 in the past 12 months.
    What is Ocean Biomedical’s market cap?
    Ocean Biomedical’s market cap is $116.18K.
      When is Ocean Biomedical’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were Ocean Biomedical’s earnings last quarter?
      Currently, no data Available
      Is Ocean Biomedical overvalued?
      According to Wall Street analysts Ocean Biomedical’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Ocean Biomedical pay dividends?
        Ocean Biomedical does not currently pay dividends.
        What is Ocean Biomedical’s EPS estimate?
        Ocean Biomedical’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Ocean Biomedical have?
        Ocean Biomedical has 232,365,140 shares outstanding.
          What happened to Ocean Biomedical’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Ocean Biomedical?
          Currently, no hedge funds are holding shares in OCEA
          What is the TipRanks Smart Score and how is it calculated?
          Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

            Company Description

            Ocean Biomedical

            Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients. The company was incorporated in 2019 and is based in Providence, Rhode Island.
            Similar Stocks
            Company
            Price & Change
            Follow
            Scinai Immunotherapeutics
            GT Biopharma
            Aditxt
            Psyence Biomedical
            Conduit Pharmaceuticals

            Ownership Overview

            <0.01%0.03%99.97%
            Insiders
            0.03% Other Institutional Investors
            99.97% Public Companies and
            Individual Investors

            Options Prices

            Currently, No data available
            ---
            Popular Stocks